American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well reported Q2 revenue of $52M (down 26.6% YoY) but improved profitability: adjusted EBITDA loss narrowed to $1.15M (vs. $4.7M loss a year ago) and net loss improved 53% YoY to $9.6M. The company raised full-year 2026 guidance to $200M–$205M revenue (from $195M–$205M) and lifted adjusted EBITDA loss to -$9M to -$7M (from -$16M to -$12M), targeting cash-flow breakeven and positive adjusted EBITDA in Q4. Separately, the Defense Health Agency issued an intent to award a sole-source contract directly to Amwell under its unified federal health IT ecosystem, supporting longer-term revenue visibility as subscriptions remain >50% of total revenue.

Analysis

The market should treat this less as a clean demand inflection and more as a credibility reset. The real value creation is in shortening the revenue chain: if direct contracting expands, intermediaries lose leverage while AMWL gains pricing power on scope and renewal timing. That said, the current quarter still looks more like expense compression plus mix repair than organic reacceleration, so the multiple can stay capped until new-logo conversion is visible in the backlog.

Second-order, the biggest winner is the company’s own platform economics, not the legacy visit business. If management can migrate even a modest share of revenue toward recurring software-like fees, incremental margins should improve sharply over the next 6-18 months; if not, the business remains a low-growth, reimbursement-sensitive services story with a better balance sheet. Competitively, health-system-focused vendors and implementation-heavy government contractors are the likely losers as buyers keep pushing for fewer integrations and more outcome accountability.

The key risk is timing slippage: a delayed award or narrower scope would puncture the 2027 growth narrative and force investors back to the current run-rate, where upside is mostly from cost cuts. What would falsify the thesis is a Q3/Q4 guide that implies churn is still bleeding faster than new subscriptions can replace it, or any indication that direct government wins do not translate into repeatable commercial conversions. In that scenario, the stock should revert from "platform optionality" to a cash-rich but still structurally challenged small-cap healthcare IT name.

Key Decisions for Investors

• Small tactical long AMWL on pullbacks over the next 1-3 weeks, sized as a catalyst trade into the expected DHA contract resolution; upside is a rerating if direct award scope broadens, but the thesis fails if timing slips beyond year-end or 2027 visibility does not improve.
• Pair trade: long AMWL / short LDOS for 1-3 months to express disintermediation risk to the pass-through integrator model; this works if government procurement keeps moving toward direct vendor relationships, and is wrong if Leidos preserves economic control over implementation.
• Do not chase the post-call pop; wait for either a contract signing headline or a retrace toward prior support before adding exposure, because the current setup is still more about narrative than booked revenue.
• Watch item, not a recommendation: if AMWL can show signed 2027 renewals or new government scope in the next 60-90 days, revisit a longer-dated long; without that, keep sizing modest because the stock remains highly dependent on a single procurement process.